At department of Surgery, Chungnam National University Hospital, from March 1991 to October 1991, a new platelet aggregation inhibitor, cilostazol, with a vasodilating action, was administered orally in daily doses of 200mg for 8 weeks in chronic
arterial occlusive diseases. After administration the clinical effects of cilostazol were observed in 10 patients with thromboangiitis obliterans and arteriosclerosis obliterans.
@ES The results were follows :
@EN 1. The overall improvement rate of the diseases was 80 percent.
2. The adverse effects of cilostazol were headache in one patient, indigestion in one patient, and overall safety rate was 80 percent.
In can be concluded that cilostazol is useful in the treatment of chronic arterial occlusive disease.
|